Description: A COVID-19 vaccine from GlaxoSmithKline Plc and Canada’s Medicago Inc. demonstrated 71 per cent efficacy against multiple variants of the disease in a positive outcome for the pandemic latecomers.
Source: BNNBloomberg.com – video report
Date: Dec 07, 2021
Questions for discussion:
- What are the advantages of this new technology?
- Do you think this product can compete against offerings from giants like Pfizer?
- How should investors treat this announcement, in your opinion?